A Single Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusion and Intravenous Bolus Administration of MK-2060 in Healthy Participants
Latest Information Update: 04 Sep 2024
At a glance
- Drugs MK 2060 (Primary)
- Indications Venous thrombosis
- Focus Adverse reactions
- Acronyms MK-2060-016
- Sponsors Merck Sharp & Dohme
- 04 Sep 2024 New trial record